3681 — Sinomab Bioscience Balance Sheet
0.000.00%
Last trade - 00:00
- HK$1.30bn
- HK$1.61bn
- CNY1.37m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 1,201 | 903 | 563 | 376 | 235 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 1,215 | 934 | 596 | 447 | 270 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 42.2 | 146 | 356 | 486 | 575 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 1,284 | 1,130 | 1,042 | 1,008 | 848 |
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 107 | 58.8 | 98.4 | 187 | 173 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Liabilities | 152 | 143 | 361 | 499 | 552 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
ESOP Debt Guarantee | |||||
Other Equity | |||||
Total Equity | 1,132 | 987 | 680 | 510 | 296 |
Total Liabilities & Shareholders' Equity | 1,284 | 1,130 | 1,042 | 1,008 | 848 |
Total Common Shares Outstanding |